



Prothena Corporation plc
Investor Relations Department
331 Oyster Point Blvd
South San Francisco, CA 94080
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: PRTA

Last Trade:	67.24
Trade Time:	4:00 PM ET Jul 21, 2017
Change:	-0.30 (-0.444%)
Day Range	67.02 - 69.53
52-Week Range	40.58 - 69.53
Volume	469,364

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jul 5, 2017*
[Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson's Disease](#)
- Jun 12, 2017*
[Prothena Announces Appointment of Wagner Zaqo, PhD as Chief Scientific Officer](#)
- May 16, 2017*
[Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer](#)
- May 9, 2017*
[Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update](#)
- May 2, 2017*
[Prothena to Report First Quarter 2017 Financial Results on May 9](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Feb 27, 2017*
[Annual Report \(10-K\)](#)
- Mar 31, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 2, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2016*
[Quarterly Report \(10-Q\)](#)